60 ID110521156 ID110521156 is a small oral molecule that directly binds to the GLP-1 receptor, as demonstrated in a surface plasmon resonance assay
The rise of the incretin therapies for obesity has attracted tremendous interest, both from drug developers and prospective patients (consumers)
The dual action of Mounjaro gives it an advantage over Ozempic as it simultaneously targets two hormone receptors involved in insulin regulation, leading to better A1C and weight reductions
It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.
According to the company, this new option could help millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card programme, those without employer coverage and those who need to self-pay outside of insurance
A small shift in recipes could mean big health gains